![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
A seamless, Phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
![](https://studyfinder.umn.edu/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBbm9FIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--c478760b452e9bdee576950e063385d5c798c0ba/Image%2010.jpg)
Recruiting
XTMAB-16 is a new, experimental drug and is part of a group of drugs known as tumor necrosis factor alpha (TNF α) inhibitors. TNF is a protein in your body that causes inflammation. TNF α inhibitors work by suppressing part of the immune response along with reducing inflammation. We are conducting this research study to see if XTMAB-16 will help in the treatment of pulmonary sarcoidosis.
Male or Female
18 years and over
Inclusion Criteria:
• Diagnosis of pulmonary sarcoidosis with some respiratory symptoms
• Must be taking 7.5 to 25 mg of prednisone daily and will to taper down dose
• Must be on an additional medication for the treatment of sarcoidosis
• Please contact umnsarc@umn.edu if you have any questions
Exclusion Criteria:
• Pregnancy or breast-feeding
Breathing, Lung & Sleep Health, Rare Diseases, Rare Diseases, Respiratory System
Clinics and Surgery Center (CSC), Sarcoidosis
Mandi DeGrote - carl1032@umn.edu
David Perlman
PHASE1
STUDY00020802
See this study on ClinicalTrials.gov